ascopubs.org

Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer.

HER2 and HER3 expression in ovarian cancer: Evolution across chemotherapy exposure and implications for targeted therapies. Median PFS by BIRC, month (95% CI) 5.49 (4.93,6.64) 2.73 (1.94,3.75) Median ...
ascopubs.org

Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with ...

Impact of body mass index on immunotherapy outcomes and complications in solid tumor patients: A real-world evidence analysis. Median progression-free survival, mo (95% CI) 4.6 (3.4, 7.4) 4.6 (3.6, ...
The New England Journal of Medicine

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...
Nature

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...
Ars Technica

Final analysis of 2025 Iberian blackout: Policies left Spain at risk

Roughly a year ago, Spain and Portugal went dark when the electrical grid of the entire Iberian Peninsula failed. While the grid operators did a heroic job of restarting the grid quickly, there were ...